Azli N, Armand J P, Rahal M, Wibault P, Boussen H, Eschwege F, Schwaab G, Gasmi J, Bachouchi M, Cvitkovic E
Institut Gustave-Roussy, Unite La Grange Villejuif, France.
Eur J Cancer. 1992;28A(11):1792-7. doi: 10.1016/0959-8049(92)90005-m.
More than 80% of undifferentiated carcinoma nasopharyngeal type patients with N3 disease (AJC-UICC 1987) will die with or from distant metastases within 3 years after the first symptom. From February 1986 to November 1987 30 consecutive patients with very advanced local disease were entered in a programme with chemotherapy-radiotherapy (CT-RT) alternation after a thorough work-up to eliminate the possibility of distant metastases.
two cycles of cisplatin 100 mg/m2 day 1, bleomycin 15 mg intravenously day 1 and 16 mg/m2 per day by continuous infusion days 1-5; 5-fluorouracil (5-FU) 650 mg/m2 per day by continuous infusion days 1-5 4 weeks apart. This was followed by two series of high-energy radiotherapy, 35 Gy/3.5 weeks, with a third chemotherapy cycle in between. 27 men and 3 women were treated, the median age was 37 years (range 17-71) and the mean WHO performance status was 1 (range 0-3). TNM classification: 15 T4, 9 T3, 6 T2, 28 N3 and 2 N2c. 18 patients had nodes larger than 8 cm and 24 had bulky bilateral cervical nodes. Toxicity for this protocol was moderate, nausea and vomiting being the main side-effects. Results after two CT cycles were 3 complete responses (CR; 10%), 22 partial responses (PR; 73%), 2 disease stabilizations, 2 progressions, and 1 patient inevaluable. Of the 30 patients, 27 patients completed the CT-RT protocol, 2 patients died before radiotherapy and 1 refused treatment after 2 days on protocol. 25 patients were in CR 3 months after the end of radiotherapy. As of August 1991, with a median follow-up of 55 months (range 43-63), there are 17 patients alive, 2 of them with active disease and 15 are NED (2 after salvage therapy).
超过80%的鼻咽未分化癌N3期患者(美国癌症联合委员会 - 国际抗癌联盟1987年分期)在出现首发症状后3年内会死于远处转移或因远处转移而死亡。1986年2月至1987年11月,30例局部病情非常严重的连续患者在经过全面检查以排除远处转移可能性后,进入了化疗 - 放疗(CT - RT)交替方案。
顺铂100mg/m²第1天,博来霉素15mg静脉注射第1天,16mg/m²持续输注第1 - 5天;5 - 氟尿嘧啶(5 - FU)650mg/m²持续输注第1 - 5天,4周为一个周期。之后进行两个疗程的高能放疗,35Gy/3.5周,中间穿插第三个化疗周期。共治疗27例男性和3例女性,中位年龄37岁(范围17 - 71岁),世界卫生组织体能状态平均为1(范围0 - 3)。TNM分期:15例T4,9例T3,6例T2,28例N3和2例N2c。18例患者淋巴结大于8cm,24例有双侧巨大颈部淋巴结。该方案的毒性为中度,恶心和呕吐是主要副作用。两个化疗周期后的结果为3例完全缓解(CR;10%),22例部分缓解(PR;73%),2例病情稳定,2例进展,1例患者无法评估。30例患者中,27例完成了CT - RT方案,2例在放疗前死亡,1例在方案治疗2天后拒绝治疗。放疗结束3个月后25例患者达到完全缓解。截至1991年8月,中位随访55个月(范围43 - 63个月),17例患者存活,其中2例有活动病灶,15例无疾病证据(2例为挽救治疗后)。